Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
HUYA Files Novel T-Cell Leukemia-Lymphoma Med in Japan
Huya Japan G.K., a local unit of US-based HUYA Bioscience International, has filed for regulatory approval of the novel investigational anticancer agent HBI-8000 (tucidinostat) in Japan for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma (ATLL), its Japanese partner…
To read the full story
Related Article
- HUYA Files HBI-8000 for PTCL in Japan: Meiji
April 8, 2021
- Meiji Gains Japan Rights for Novel Blood Cancer Treatment from HUYA Bioscience
January 10, 2020
BUSINESS
- Daiichi Targets 3 Trillion Yen Sales by FY2030, Global Top-5 Oncology Spot
May 12, 2026
- Lilly Japan Hits Record Sales as Mounjaro Tops 100 Billion Yen
May 12, 2026
- Ferring Nabs Japan Approval for Bladder Cancer Gene Therapy
May 12, 2026
- Teijin to Offload Legacy Drug Portfolio as It Speeds Up Pivot to Rare Diseases
May 12, 2026
- Keytruda Extends Run as Japan’s Best-Selling Drug in April: Encise
May 12, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…